FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL										
	OMB Number:	3235-028									
- 1	Estimated average	hurdon									

0.5

hours per response:

Check this box if no longer subject	tc
Section 16. Form 4 or Form 5	
obligations may continue. See	
Instruction 1(h)	

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

					or s	Section	on 30(h) d	of the	Investment C	Company Act	of 1940							
1. Name and Address of Reporting Person* FOUSE JACOUALYN A						2. Issuer Name and Ticker or Trading Symbol AGIOS PHARMACEUTICALS INC AGIO							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last) (First) (Middle) C/O AGIOS PHARMACEUTICALS, INC. 88 SIDNEY STREET (Street) CAMBRIDGE MA 02139				AC	X Director Offices below								(give title		10% Ov Other (s below)			
				05/	/31/2	.018		saction (Mon		6.1			n Filing		nlicable			
					If Amendment, Date of Original Filed (Month/Day/Year)							Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	ity) (State) (Zip)							. 0.00										
		Tab	le I - Nor	n-Deriv	ative	Se	curities	s Ac	quired, D	isposed (of, or Be	neficial	ly Owne	k				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D						Execution Date,			Code (Instr. 5)				Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership	
									Code V	Amount	(A) o (D)	r Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)	
		٦							uired, Dis s, options				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	Date (Month/Day/Year) i	3A. Deemed Execution Date, if any (Month/Day/Year)	Date,	4. Transactio Code (Inst				6. Date Exerc Expiration Day (Month/Day/	ate	7. Title and Amount of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e s lly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				,	Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares						
Stock option (right to buy)	\$93.5	05/31/2018			A		5,700		(1)	05/30/2028	Common stock	5,700	\$0.00	5,700)	D		
Restricted	(2)	05/31/2018			Α	_	1,400		(3)	(3)	Common	1,400	\$0.00	1,400		D		

Explanation of Responses:

- 1. This option was granted on May 31, 2018. The shares underlying this option vest as to 100% of the underlying shares on May 31, 2019.
- 2. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- 3. The restricted stock units were granted on May 31, 2018. The shares underlying the stock units will vest in full on May 31, 2019. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Remarks:

/s/ William Cook, as Attorneyin-fact for Jacqualyn Fouse 06/04/2018

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.